US Esoteric Testing Market Size and Forecasts (2020 – 2030)

US Esoteric Testing Market Size and Forecasts (2020 – 2030), Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type (Infectious Disease Testing, Endocrinology Testing, Oncology Testing, Toxicology Testing, Immunology Testing, Neurology Testing, and Others), Technology (Chemiluminescence Immunoassay, Enzyme-Linked Immunosorbent Assay, Mass Spectrometry, Real-Time PCR, DNA Sequencing, Flow Cytometry, and Others), and End User (Hospitals & Laboratories and Independent & Reference Laboratories))

Send Enquiry
Item ID: TIPRE00031812 Category: Tags: , ,

$2,485$3,885

Description

The US Esoteric Testing market is expected to grow from US$ 10.382 billion in 2022 to US$ 31.274 billion by 2030; it is estimated to grow at a CAGR of 14.8% from 2022 to 2030. The report highlights trends prevailing in the market and factors driving the market growth. The market growth is attributed to the rising prevalence of chronic diseases and growing awareness of early detection of medical conditions, which are driving the US’s esoteric testing market size and growth. Additionally, advancements in genetic testing and rare disease-related initiatives by regulatory authorities are likely to emerge as a significant trend in the market during the forecast period. However, the lack of skilled personnel and the high cost of procedure hinder market growth during the forecast period 2022-2030.
Growing Awareness of Early Detection of Medical Conditions drives the market in the forecast period.
The early diagnosis of diseases helps medical professionals and patients to make various important medical decisions in terms of care, support needs, and financial and legal matters. Obtaining accurate and early diagnosis after noticing cognitive symptoms related to a specific medical condition results in the reversal of symptoms before they are aggravated, followed by an effective and early treatment of patients. It also provides healthcare professionals sufficient time for better decision-making. Laboratory examination procedures are widely performed for the diagnosis of diseases associated with medical specialties, such as neurological disorders, genetic diseases, cancer, and endocrinological disorders. Esoteric testing and genetic testing are performed for the diagnosis of diabetes, cardiovascular disease, lipid disorders, cancer, and genetic diseases.
Various government regulatory bodies are also taking initiatives and conducting campaigns to promote early diagnosis practices. The National Organization for Rare Disorders aims to identify, diagnose, and treat rare disorders through numerous supportive programs, including education, research, advocacy, and patient services. The New York State Rare Disease Workgroup, created in response to legislation passed in New York State (Article 27-L of the Public Health Law), aims to identify best practices that could enhance the awareness of rare diseases. Through such initiatives, people potentially having rare diseases can be referred to specialists, and barriers to their treatments, including financial challenges, can be addressed. Such initiatives to build knowledge regarding available diagnosis options for complex genetic and non-genetic rare disorders favor the growth of the US esoteric testing market.
Report Segmentation and Scope –
The “US Esoteric Testing market” is segmented on the basis of type, technology, and end user. Based on type, the market is segmented into infectious disease testing, endocrinology testing, oncology testing, toxicology testing, immunology testing, neurology testing, and others. In terms of technology, the US esoteric testing market is divided into chemiluminescence immunoassay, enzyme-linked immunosorbent assay, mass spectrometry, real-time PCR, DNA sequencing, flow cytometry, and others. In terms of end users, the market is categorized into hospitals and laboratories and independent and reference laboratories.
The US esoteric testing market, by type, is segmented into infectious disease testing, endocrinology testing, oncology testing, toxicology testing, immunology testing, neurology testing, and others. The oncology testing segment held the largest market share in 2022. The infectious disease testing segment is anticipated to register the highest CAGR from 2022 to 2030.
Based on technology, the US esoteric testing market is segmented into chemiluminescence immunoassay, enzyme-linked immunosorbent assay, mass spectrometry, real-time PCR, DNA sequencing, flow cytometry, and others. The chemiluminescence immunoassay segment held the largest market share in 2022. The enzyme-linked immunosorbent assay segment is anticipated to register the highest CAGR of 18.7% during 2022–2030.
Based on end users, the US esoteric testing market is segmented into hospitals and laboratories, as well as independent and reference laboratories. The hospitals and laboratories segment held a larger share of the market in 2022. It is further expected to register a higher CAGR of 15.2% during 2022–2030.
Esoteric tests are generally performed for the analysis of rare and unique substances that are not concluded in regular tests. To perform these tests, clinical laboratories require expertise in relevant specialties. Therefore, large commercial laboratories outsource these complex tests to reference and esoteric testing laboratories. A few of the labs performing esoteric testing in the US include Quest Diagnostics Incorporated, Mayo Medical Laboratories, ARUP Laboratories, Myriad Genetics, Genomic Health, Foundation Medicine, and Laboratory Corporation of America. The number of laboratories that can perform these specialized tests is increasing in the region.
As per an article by the Endocrine Society, published in January 2022, hypogonadism is a common condition in the male population, with a higher prevalence in older men, obese men, and men with type 2 diabetes. 35% of men older than 45 years of age and 30–50% of men with type 2 diabetes or obesity are estimated to have hypogonadism. Moreover, as per the US Census Bureau’s estimation, the incidences of hypogonadism in men aged 65 years and more grew from ~35 million in 2000 to ~55 million by 2020. Further, it is estimated to rise to ~87 million by 2050. The surging prevalence of this condition is due to the rise in the geriatric population in the US.
An upsurge in the demand for esoteric testing is also attributed to the rising cases of hepatic cirrhosis. As per Statista, 51,642 adults in the US died from liver disease in 2020. Chronic liver disease/cirrhosis was the 12th leading cause of mortality in the US in 2020; an increase in the incidences of alcoholic cirrhosis is a major risk factor for this disease.
Furthermore, collaborations and partnerships are also expected to propel the market growth of esoteric testing in the US. For instance, as per The National Institutes of Health (NIH) press release of October 2021, NIH, the US Food and Drug Administration, ten pharmaceutical companies, and five non-profit organizations have joined to fasten the development of gene therapies for the 30 million Americans who suffer from rare diseases. Whereas there are nearly 7,000 rare diseases, currently, only 2 heritable diseases have FDA-approved gene therapies. The recently launched Bespoke Gene Therapy Consortium (BGTC), a section of the NIH Accelerating Medicines Partnership (AMP) program and project-lead by the Foundation of NIH, aims to enhance and streamline the development process of gene therapy to support the unmet medical needs of people with rare diseases.
Thus, the burgeoning cases of hypogonadism, hepatic cirrhosis, and other such disease is driving the growth of the esoteric testing market in the US.
Companies in the US’s esoteric testing market adopt various organic and inorganic strategies. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players strengthen their customer base and expand their product portfolios. A few of the significant developments by key players in the US’s esoteric testing market are listed below.
The American Heart Association, The American Thyroid Association, The United States Food and Drug Administration (FDA), MyBioSource.com., The Endocrine Society National Institutes of Health (NIH) are a few of the major primary and secondary sources referred to while preparing the report on the US Esoteric Testing market.

Summary Info

Industry:

Number of pages:

Pricing options:

, ,

Publishing status:

Geographical coverage:

Year of Publication:

Chemiluminescence Immunoassay Segment to Account for Largest Market Share by Technology in US Esoteric Testing Market during 2022–2030

According to our new research study on ” US Esoteric Testing Market Size and Forecast (2020–2030), Country Share, Trend, and Growth Opportunity Analysis – by Type, Technology, and End User,” the market is expected to grow from US$ 10.382 billion in 2022 to US$ 31.274 billion by 2030; the market is estimated to record a CAGR of 14.8% during 2022–2030. The report highlights the major factors driving the US’s esoteric testing market growth and prominent players with their developments in the market.

Based on technology, the US esoteric testing market is segmented into chemiluminescence immunoassay, enzyme-linked immunosorbent assay, mass spectrometry, real-time PCR, DNA sequencing, flow cytometry, and others. The chemiluminescence immunoassay segment held the largest market share in 2022. The enzyme-linked immunosorbent assay segment is anticipated to register the highest CAGR of 18.7% during 2022–2030. An immunoassay exploits the principles of biochemistry for the detection and measurement of an analyte, which can be large proteins, antibodies (produced in response to an infection), or small molecules. These highly adaptable assays can be applied to determine various types of analytes, depending on the needs of users. Chemiluminescent immunoassays are a type of standard enzyme immunoassays (EIA), representing the application of biochemical techniques in immunology.
Direct chemiluminescent methods use luminophore markers, while indirect methods use enzyme markers. The key advantages of chemiluminescent analytical methods include a wide application range, high signal intensity, absence of interfering emissions (high specificity), rapid acquisition of analytical signals, high stability of reagents and their conjugates, low consumption of reagents, random access, reduced incubation time, and full compatibility with immunology assay protocols.

The US esoteric testing market, by type, is segmented into infectious disease testing, endocrinology testing, oncology testing, toxicology testing, immunology testing, neurology testing, and others. The oncology testing segment held the largest market share in 2022. The infectious disease testing segment is anticipated to register the highest CAGR from 2022 to 2030. Infectious diseases are transmitted in multiple ways; thus, on-time diagnosis and treatment are the key to limiting their transmission. Laboratory tests are the only way to confirm the diagnosis of an infection. Some inexpensive and convenient blood tests can diagnose Influenza, Lyme disease, Epstein-Barr virus infection, and so on. Disease-causing bacteria and viruses are easily identified by genetic testing. Major types of tests performed in labs include culturing, microscopy, immunologic tests, nucleic acid–based identification methods, and non-nucleic acid-based identification methods.
Polymerase chain reaction (PCR) is an example of an esoteric test employed for the identification of infectious diseases. This technique is employed to make multiple copies of a particular gene from the infection-causing microorganisms, making their identification easy. PCR tests are the “gold standard” in COVID-19 testing. As per Our World in Data stats, 909.44 million RT-PCR tests were performed in the US till June 2022.

Based on end users, the US esoteric testing market is segmented into hospitals and laboratories, as well as independent and reference laboratories. The hospitals and laboratories segment held a larger share of the market in 2022. It is further expected to register a higher CAGR of 15.2% during 2022–2030. Almost all hospitals have a laboratory whose operations are proportional in size to the population they serve. Hospital laboratories need to process hundreds of samples in a limited timeframe. This includes all the tests that are required during emergencies and are conducted in high volumes, such as cardiac biomarker (troponin) tests, wherein results are needed rapidly for effective patient care. The workload in hospital labs can be divided on the basis of the type of testing. These facilities are staffed by personnel trained in particular specialties, which mainly include hematology, microbiology, chemistry, and blood banking. Other units may perform specialized tests using electron microscopy and immunohistochemistry, with a focus on surgical pathology and cytology (analyzing cell and tissue structure). Mayo Clinic in Rochester (US) is among the best facilities for the diagnosis of diabetes and endocrinology in the US. The clinic performs esoteric testing for endocrinology.

Georgia Esoteric & Molecular Laboratory LLC, Laboratory Corp of America Holdings, Quest Diagnostics Inc., National Medical Services Inc., OPKO Health Inc., ARUP Laboratories Inc., bioMONTR Labs, Athena Esoterix LLC, Stanford Hospital & Clinics, and Foundation Medicine Inc., among others are among the key companies operating in the US Esoteric Testing market.

Companies operating in the US’s esoteric testing market adopt various organic and inorganic strategies. Organic strategies mainly include product launch expansion and business planning. Mergers & acquisitions, partnerships, and collaborations are among the inorganic growth strategies witnessed in the US Esoteric Testing market. These developments allow the market players to expand their businesses, thereby contributing to the overall growth of the US esoteric testing market.
A few of the significant developments by key US Esoteric Testing market players are listed below.

• In March 2022, Waters Corporation launched the Xevo TQ Absolute system, a highly sensitive and compact benchtop tandem mass spectrometer. This latest mass spectrometer quantifies negatively ionizing compounds with up to 15 times greater sensitivity than its predecessor, with a 45% smaller size. Moreover, it consumes up to 50% less electricity and gas.
• In February 2021, Quest Diagnostics collaborated with Grail for its Galleri multicancer blood tests. Quest Diagnostics had plans to provide phlebotomy services using the Galleri multicancer early-detection blood tests.
• In January 2021, BioReference Laboratories, Inc., an OPKO Health (OPK) company, introduced Scarlet Health. It is an in-home, fully integrated digital platform that provides access to on-demand diagnostic services. Similar to devices that are used on a daily basis, Scarlet has been designed to confer ease of use, ubiquity, and convenience. The platform delivers an innovative, flexible, mobile alternative to traditional patient service centers or other draw locations when phlebotomy and other specimen collection services are needed.
• In September 2021, LabCorp acquired operating assets and intellectual property (IP) from Myriad Genetics’ autoimmune business unit, including the Vectra rheumatoid arthritis (RA) assay. With this acquisition, LabCorp is expected to bolster its scientific leadership in rheumatology.
• In 2020, Quest Diagnostics acquired Blueprint Genetics, an outreach laboratory service business of Memorial Hermann Health System. Via this multiyear acquisition agreement, Quest plans to offer professional laboratory management services for all 21 hospital laboratories of Memorial Hermann, which provide onsite rapid-response testing. Quest also plans to become the sole laboratory service provider for the Memorial Hermann Health Plan.
• In 2019, Sonic Healthcare acquired Aurora Diagnostics to augment its presence in the anatomical pathology specialty in the US.

?

– Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific frozen waffles market.
– Highlights key business priorities in order to assist companies to realign their business strategies.
– the key findings and recommendations highlight crucial progressive industry trends in Asia Pacific frozen waffles market, thereby allowing players across the value chain to develop effective long-term strategies.
– develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
– Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
– Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific FGD Gypsum Market Landscape
4.1 Overview
4.2 Porter’s Five Forces Analysis
4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
5. Asia Pacific FGD Gypsum Market – Key Industry Dynamics
5.1 Market Drivers
5.1.1 Growing Construction Industry
5.1.2 Rising Preference for Gypsum Board in Construction Industry
5.2 Market Restraints
5.2.1 Availability of Alternative Materials
5.2.2 Gradual Phase-Out of Coal-Fired Power Plants
5.3 Market Opportunities
5.3.1 Circular Economy and Waste Management
5.4 Future Trends
5.4.1 Product Innovation Pertaining FGD Gypsum
5.5 Impact of Drivers and Restraints:
6. FGD Gypsum Market – Asia Pacific Market Analysis
6.1 Asia Pacific FGD Gypsum Market Revenue (US$ Million), 2022 – 2030
6.2 FGD Gypsum Market Forecast and Analysis
7. Asia Pacific FGD Gypsum Market Analysis – Application
7.1 FGD Gypsum Market, by Application (2022 and 2030)
7.2 Wallboard/Drywall
7.2.1 Overview
7.2.2 Wallboard/Drywall Market – Volume and Forecast to 2030 (Kilo Tons)
7.2.3 Wallboard/Drywall Market – Revenue and Forecasts to 2030 (US$ Million)
7.3 Cement
7.3.1 Overview
7.3.2 Cement Market – Volume and Forecast to 2030 (Kilo Tons)
7.3.3 Cement Market – Revenue and Forecasts to 2030 (US$ Million)
7.4 Agriculture
7.4.1 Overview
7.4.2 Agriculture Market – Volume and Forecast to 2030 (Kilo Tons)
7.4.3 Agriculture Market – Revenue and Forecasts to 2030 (US$ Million)
7.5 Water Treatment
7.5.1 Overview
7.5.2 Water Treatment Market – Volume and Forecast to 2030 (Kilo Tons)
7.5.3 Water Treatment Market – Revenue and Forecasts to 2030 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others Market Volume and Forecast to 2030 (Kilo Tons)
7.6.3 Others Market Revenue and Forecasts to 2030 (US$ Million)
8. Asia Pacific FGD Gypsum Market – Country Analysis
8.1 Asia Pacific
8.1.1 Overview
8.1.2 Asia Pacific FGD Gypsum Market Breakdown by Country
8.1.2.1 FGD gypsum market Breakdown by Country
8.1.2.2 Australia FGD Gypsum Market Volume and Forecasts To 2030 (Kilo Tons)
8.1.2.3 Australia FGD Gypsum Market Revenue and Forecasts To 2030 (US$ Million)
8.1.2.3.1 Australia FGD Gypsum Market Breakdown by Application
8.1.2.3.2 Australia FGD Gypsum Market Breakdown by Application
8.1.2.4 China FGD Gypsum Market Volume and Forecasts To 2030 (Kilo Tons)
8.1.2.5 China FGD Gypsum Market Revenue and Forecasts To 2030 (US$ Million)
8.1.2.5.1 China FGD Gypsum Market Breakdown by Application
8.1.2.5.2 China FGD Gypsum Market Breakdown by Application
8.1.2.6 India FGD Gypsum Market Volume and Forecasts To 2030 (Kilo Tons)
8.1.2.7 India FGD Gypsum Market Revenue and Forecasts To 2030 (US$ Million)
8.1.2.7.1 India FGD Gypsum Market Breakdown by Application
8.1.2.7.2 India FGD Gypsum Market Breakdown by Application
8.1.2.8 Japan FGD Gypsum Market Volume and Forecasts To 2030 (Kilo Tons)
8.1.2.9 Japan FGD Gypsum Market Revenue and Forecasts To 2030 (US$ Million)
8.1.2.9.1 Japan FGD Gypsum Market Breakdown by Application
8.1.2.9.2 Japan FGD Gypsum Market Breakdown by Application
8.1.2.10 South Korea FGD Gypsum Market Volume and Forecasts To 2030 (Kilo Tons)
8.1.2.11 South Korea FGD Gypsum Market Revenue and Forecasts To 2030 (US$ Million)
8.1.2.11.1 South Korea FGD Gypsum Market Breakdown by Application
8.1.2.11.2 South Korea FGD Gypsum Market Breakdown by Application
8.1.2.12 Rest of Asia Pacific FGD Gypsum Market Volume and Forecasts To 2030 (Kilo Tons)
8.1.2.13 Rest of Asia Pacific FGD Gypsum Market Revenue and Forecasts To 2030 (US$ Million)
8.1.2.13.1 Rest of Asia Pacific FGD Gypsum Market Breakdown by Application
8.1.2.13.2 Rest of Asia Pacific FGD Gypsum Market Breakdown by Application
9. Competitive Landscape
9.1 Heat Map Analysis By Key Players
9.2 Company Positioning & Concentration
10. FGD Gypsum Market Industry Landscape
10.1 Overview
10.2 Market Initiative
10.3 New Product Development
10.4 Merger and Acquisition
11. Company Profiles
11.1 EP Power Minerals GmbH
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 CASEA GmbH
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Holcim Ltd
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Knauf Gips KG
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Travancore Titanium Products Ltd
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Compagnie de Saint Gobain SA
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
12. Appendix

LIST OF TABLES

Table 1. US Esoteric Testing Market Segmentation
Table 2. US Esoteric Testing Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 3. US Esoteric Testing Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 4. US Esoteric Testing Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 5. Organic Developments in the US Esoteric Testing Market
Table 6. Inorganic Developments in the US Esoteric Testing Market
Table 7. Glossary of Terms, US Esoteric Testing Market

LIST OF FIGURES

Figure 1. US Esoteric Testing Market Segmentation
Figure 2. US – PEST Analysis
Figure 3. US Esoteric Testing Market: Key Industry Dynamics
Figure 4. US Esoteric Testing Market: Impact Analysis of Drivers and Restraints
Figure 5. US Esoteric Testing Market Revenue (US$ Mn), 2020 – 2030
Figure 6. US Esoteric Testing Market Revenue Share, by Technology 2022 & 2030 (%)
Figure 7. Chemiluminescence Immunoassay: US Esoteric Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Enzyme-Linked Immunosorbent Assay: US Esoteric Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Mass Spectrometry: US Esoteric Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Real-Time PCR: US Esoteric Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Flow Cytometry: US Esoteric Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. DNA Sequencing: US Esoteric Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: US Esoteric Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. US Esoteric Testing Market Revenue Share, by Type 2022 & 2030 (%)
Figure 15. Infectious Disease Testing: US Esoteric Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Endocrinology Testing: US Esoteric Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Oncology Testing: US Esoteric Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Toxicology Testing: US Esoteric Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Immunology Testing: US Esoteric Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Neurology Testing: US Esoteric Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Others: US Esoteric Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. US Esoteric Testing Market Revenue Share, by End User 2022 & 2030 (%)
Figure 23. Hospitals & Laboratories: US Esoteric Testing Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Independent & Reference Laboratories: US Esoteric Testing Market – Revenue and Forecast to 2030 (US$ Million)

The List of Companies – US Esoteric Testing Market
– Georgia Esoteric & Molecular Laboratory LLC
– Laboratory Corp of America Holdings
– Quest Diagnostics Inc
– National Medical Services Inc
– OPKO Health Inc
– ARUP Laboratories Inc
– bioMONTR Labs
– Athena Esoterix LLC
– Stanford Hospital & Clinics
– Foundation Medicine Inc

Reviews

There are no reviews yet.

Be the first to review “US Esoteric Testing Market Size and Forecasts (2020 – 2030)”